Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

*Press release courtesy of University Health Network



(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples. The discovery also identifies a new opportunity for targeted therapy.

The findings are published online today in Nature Genetics. The research shows how an acquired mutation involving the fusion of two genes (TMPRSS2 and ERG) can change the epigenetic identity of tumours leading to some genes being turned on while others are turned off, says DR. Mathieu Lupien, corresponding author and Senior Scientist at Princess Margaret  Cancer Centre, University Health Network, and a member of its Cancer Epigenetics Program, a team focused on breaking the code of cancer.

Dr. Lupien, who is also an Associate Professor in the Department of Biomedical Physics, University of Toronto, talks about the research in the video below.
 

The discoveries highlight the power of mutations to influence epigenetics in prostate tumours to change the identity of cancer cells. Dr. Lupien's team exploited this fact to identify mechanisms that drive development of fusion-positive prostate cancer.

"Our findings specifically show that fusion-positive prostate cancer is dependent on the NOTCH signalling pathway, which can be blocked chemically in pre-clinical models," says Dr. Lupien. "This identifies a promising druggable target against fusion-positive prostate cancer and takes us a step closer to providing personalized cancer medicine for up to 50% of prostate cancer patients," he says.

"We're hopeful this research can be translated into clinical care in the near future to offer patients an additional, tailored treatment to complement the current standard of care, based on their fusion profile."

The study team consisted of scientists, pathologists and clinician-scientists involved in the Canadian Prostate Cancer Genome Network (CPC-GENE), the world-leading prostate cancer sequencing program co-led by Dr. Robert Bristow at the Princess Margaret Cancer Centre and Dr. Paul Boutros at the Ontario Institute for Cancer Research.

The research published today was supported by the Movember Foundation through Prostate Cancer Canada, the Ontario Institute for Cancer Research funded by the Government of Ontario, and The Princess Margaret Cancer Foundation.
 
-30-

About Prostate Cancer Canada

Prostate Cancer Canada is the leading national foundation dedicated to the elimination of the most common cancer in men through research, advocacy, education, support and awareness. As one of the largest investors in prostate cancer research in Canada, Prostate Cancer Canada is committed to continuous discovery in the areas of prevention, diagnosis, treatment, and support.

For more information:

Adam Miller
Prostate Cancer Canada
416-441-2131 ext. 235
adam.miller@prostatecancer.ca



Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive